Oragenics, Inc. — Q2 2011 Form 10-Q
Business and period: Biotechnology and probiotic nutraceutical company focused on oral-health products, including commercializing ProBiora3, and developing SMaRT Replacement Therapy, the antibiotic candidate MU1140-S, and other technologies. This unaudited filing covers the quarter and six months ended June 30, 2011; comparisons are to the same periods in 2010 unless noted.
Financial performance
| Metric | Q2 2011 | Q2 2010 | Six months 2011 | Six months 2010 |
|---|---|---|---|---|
| Revenue | $347,569 | $304,696 | $697,506 | $646,179 |
| Gross profit | $18,752 | $177,276 | $273,712 | $319,858 |
| Gross margin | 5.4% | 58.2% | 39.2% | 49.5% |
| Operating loss | $(2,304,374) | $(2,009,191) | $(3,819,761) | $(3,757,606) |
| Net loss | $(2,373,243) | $(2,010,222) | $(3,932,256) | $(3,757,421) |
| Basic and diluted loss per share | $(0.42) | $(0.37) | $(0.69) | $(0.70) |
- Six-month ProBiora3 product revenue was $595,317, up from $521,115. Total revenue growth was partly offset by increased returns and allowances and lower grant revenue.
- Q2 cost of sales rose to $328,817 from $127,420, including $167,617 of scrap expense associated with product-transition costs. Six-month cost of sales was $423,794, including $152,144 of product-transition scrap expense.
- Six-month research and development expense increased to $1,044,264 from $909,838, principally due to SMaRT clinical-trial and LPT3-04 work. Selling, general and administrative expense declined to $3,049,209 from $3,167,626, reflecting lower consulting and marketing costs, partly offset by higher compensation and stock-based expense.
- Cash used in operating activities was $2,584,733, versus $3,281,330 in the first half of 2010. Financing provided $2,452,630; investing used no cash. Cash and cash equivalents were zero at June 30, 2011, with restricted cash of $440,759.
- At June 30, assets totaled $1,307,124 and liabilities $6,292,504; shareholders’ deficit was $4,985,380. Working-capital deficit was $673,454. The company reported $4.5 million outstanding under its convertible revolving facility and $65,626 of short-term notes payable. Accounts payable and accrued expenses were $1,611,284.
Changes, outlook, and significant risks
- Revenue increased, but gross profit and gross margin fell sharply in Q2, mainly due to higher scrap costs and product-transition expenses. Six-month net loss widened to $3.93 million from $3.76 million.
- The Koski Family Limited Partnership credit facility was expanded to $7 million, at LIBOR plus 6%, with outstanding amounts potentially converting automatically on the terms of a future securities offering. Subsequent to quarter-end, the company borrowed $500,000 in July and $1 million on August 1; it reported $6 million outstanding and $1 million remaining availability after those borrowings.
- Management said available resources and facility access were expected to support the current plan through December 2011, but the company lacked sufficient capital to fund operations beyond then and needed additional financing. It warned that unavailable or unacceptable financing could force it to curtail development, reduce costs, or cease operations. The 2010 auditor’s report had raised substantial doubt about the company’s ability to continue as a going concern.
- Management expected continued losses and increased research and development spending. It anticipated completing the second Phase 1 SMaRT trial in the second half of 2011, subject to enrollment; LPT3-04 study results were expected in Q4 2011. MU1140-S preclinical testing and an IND filing were planned for 2012, subject to capital availability. These are forward-looking plans, not assured outcomes.
- The company was withdrawing from remaining mass-retail customers and shifting sales efforts toward direct-to-consumer, professional offices, private label, international distribution, and licensing. Packaging changes could increase near-term costs; management expected potential longer-term product-cost and sales benefits. Inventory and sales-return reserves were $167,614 and $201,957, respectively.
- Key risks include dependence on financing and a related-party lender, ongoing losses, product-development and regulatory uncertainty, limited commercialization resources, supplier concentration, and possible dilution. Disclosure controls were deemed ineffective because material weaknesses remained, including limited control documentation, insufficient staff for segregation of duties, and inadequate formal accounting policies. Management reported progress on remediation but had not resolved the weaknesses.
- No material non-ordinary-course legal proceedings were reported. The filing reported no defaults upon senior securities.
Investor verification priorities
- Confirm current cash, restricted-cash availability, facility borrowings and remaining capacity, and the company’s financing needs beyond December 2011.
- Review the facility’s related-party terms, conversion provisions, maturity, and any subsequent amendments or draws.
- Assess whether product-transition costs, returns, and inventory reserves continue to pressure gross margin and cash flow.
- Track clinical-trial enrollment and results, regulatory milestones, and whether planned development can be funded.
- Monitor remediation of internal-control material weaknesses and the status of going-concern risk.
- Reconcile the filing’s differing six-month R&D expense figures: the financial statements report $1,044,264, while MD&A states $1,044,164.